Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28798997 | 0.83 | NOTUM (0.39) | NOTUMTSHRRAB9AL3MBTL1SLC22A12 | |
| SCHEMBL30109124 | 0.81 | NOTUM (0.39) | NOTUMTSHRRAB9AL3MBTL1SLC22A12 | |
| SCHEMBL4167876 | 0.81 | NOTUM (0.39) | NOTUMTSHRRAB9AL3MBTL1SLC22A12 | |
| SCHEMBL30109225 | 0.80 | KMT2A (0.42) | TSHRRAB9AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL2117227 | 0.80 | KMT2A (0.42) | TSHRRAB9AL3MBTL1ALDH1A1HPGD | |
| SCHEMBL30405639 | 0.79 | RAB9A (0.41) | NOTUMTSHRRAB9AL3MBTL1OXER1 | |
| SCHEMBL27550174 | 0.79 | OXER1 (0.51) | NOTUMTSHRRAB9AL3MBTL1OXER1 | |
| SCHEMBL15971447 | 0.78 | NOTUM (0.41) | NOTUMTSHRRAB9AL3MBTL1SLC22A12 | |
| SCHEMBL21055089 | 0.78 | TSHR (0.40) | NOTUMTSHRRAB9AL3MBTL1OXER1 | |
| SCHEMBL31056496 | 0.78 | NR4A1 (0.46) | NOTUMTSHRRAB9AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223277-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS PHARMA AG (CH) | 2025-07-10 | — | — | US | disclosed |
| CN-120081822-A | Substituted indole compounds and methods of use thereof | 诺瓦提斯药物公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025068951-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-119698414-A | Indole-phenyl piperidine compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025054361-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-119569730-A | Complement factor B inhibitor, pharmaceutical composition and application thereof | 天地恒一制药股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4504699-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4346812-A2 | SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF | Chinook Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024049977-A1 | SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF | CHINOOK THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2015009616-A1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| US-7589097-B2 | Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-09-25 | — | — | US | disclosed |
| US-7405219-B2 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2007-03-01 | — | — | US | disclosed |
| US-7141575-B2 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | disclosed |
| EP-1392312-A1 | TRIAZOLO 4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002055083-A1 | TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | NOTUM 3268/4885TSHR 219/4885RAB9A 1703/4885 |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | NOTUM 2972/4885TSHR 185/4885RAB9A 2025/4885 |
| US-20250223277-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | CFB, CFH, C1QBP | NOTUM 2073/4885TSHR 3778/4885RAB9A 2292/4885 |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | NOTUM 3575/4885TSHR 244/4885RAB9A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.